Mikhail Blagosklonny is a world class scientist who is internationally famous for his research on aging and cancer. He works at Roswell Park Cancer Institute, New York as professor of oncology. This institute is the oldest cancer treatment and research facility in the United States. Mikhail Blagosklonny was born in Russia. He went to First Pavlov State Medical University in St. Peterburg to become a doctor. From there, he acquired an M.D. degree in internal medicine and Ph.D. degree in cardiology and experimental medicine.
In 2002, Blagosklonny joined New York Medical College in Valhalla, New York as an associate professor of medicine. Later, he joined Ordway Research Institute in Albany, New York as a senior scientist. In 2009, Blagosklonny joined Roswell Park Cancer Institute as professor of oncology on researchgate.net. His prime area of interest in research has always been cancer. He has worked a lot on targeted cancer therapies that avoid damage to normal cells. His other area of interest in research is aging.
Mikhail Blagosklonny has proposed using rapamycin for increasing human life. Rapamycin is a popular drug which is used for treating cancer. In the world of medicine science, Blagosklonny is known as a strong advocate for rapamycin who believes it results in longevity. As a result, he has formulated a hypothesis which states the role of TOR signaling in cancer and aging.
Blagosklonny also works with popular medical science journals. He is editor-in-chief of three journals: Oncotarget, Cell cycle, and Aging. In addition to this, he is also an associate editor of popular medicine science journal Cancer Biology & Therapy. Mikhail Blagosklonny is an editorial board member of Cell Death & Differentiation, Autophagy, Am J Pathology, International J Cancer, and PLOS ONE. He is also the founder of Cell Cycle on tandfonline.com. In peer-reviewed journals, Blagosklonny has authored more than 270 articles.
There is no successful person in the world that has not faced criticism. This is also true for Professor Blagosklonny. He has been criticized by fellow scientists in different ways. One of them criticized the reviewing process of Oncotarget whose editor-in-chief is Blagosklonny. He alleged that Mikhail Blagosklonny encourages authors to include references to his publications in their articles. As a result, Mikhail Blagosklonny’s personal impact factor increases to a great level.